Acadian Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $23.1M | Sell |
591,686
-74,740
| -11% | -$2.31M | 0.03% | 388 |
|
|
2026
Q1 | $18M | Buy |
666,426
+172,822
| +35% | +$5.81M | 0.03% | 396 |
|
|
2025
Q4 | $21.1M | Sell |
493,604
-192,114
| -28% | -$7.24M | 0.03% | 328 |
|
|
2025
Q3 | $19.4M | Buy |
685,718
+62,714
| +10% | +$1.88M | 0.03% | 338 |
|
|
2025
Q2 | $11.7M | Buy |
623,004
+57,959
| +10% | +$1.1M | 0.02% | 400 |
|
|
2025
Q1 | $10.2M | Buy |
565,045
+188,679
| +50% | +$3.83M | 0.03% | 329 |
|
|
2024
Q4 | $6.33M | Sell |
376,366
-45,414
| -11% | -$871K | 0.02% | 453 |
|
|
2024
Q3 | $6.82M | Sell |
421,780
-128,358
| -23% | -$1.51M | 0.02% | 420 |
|
|
2024
Q2 | $4.52M | Buy |
550,138
+3,620
| +0.7% | +$37.9K | 0.01% | 529 |
|
|
2024
Q1 | $8.09M | Buy |
546,518
+84,342
| +18% | +$1.14M | 0.03% | 357 |
|
|
2023
Q4 | $6.7M | Sell |
462,176
-3,898
| -0.8% | -$39.9K | 0.03% | 382 |
|
|
2023
Q3 | $5.03M | Buy |
466,074
+7,923
| +2% | +$95.3K | 0.02% | 433 |
|
|
2023
Q2 | $5.91M | Buy |
458,151
+85,795
| +23% | +$1.16M | 0.02% | 411 |
|
|
2023
Q1 | $4.91M | Buy |
372,356
+18,206
| +5% | +$289K | 0.02% | 459 |
|
|
2022
Q4 | $5.31M | Buy |
354,150
+134,964
| +62% | +$1.24M | 0.03% | 425 |
|
|
2022
Q3 | $2.58M | Sell |
219,186
-2,641
| -1% | -$35.7K | 0.01% | 561 |
|
|
2022
Q2 | $2.51M | Buy |
221,827
+140,548
| +173% | +$2.82M | 0.01% | 572 |
|
|
2022
Q1 | $2.43M | Buy |
81,279
+22,742
| +39% | +$616K | 0.01% | 622 |
|
|
2021
Q4 | $1.55M | Buy |
+58,537
| New | +$1.77M | 0.01% | 721 |
|
|
2021
Q1 | – | Sell |
-16,964
| Closed | -$594K | – | 2285 |
|
|
2020
Q4 | $594K | Sell |
16,964
-103,669
| -86% | -$3M | ﹤0.01% | 1172 |
|
|
2020
Q3 | $2.9M | Sell |
120,633
-20,472
| -15% | -$503K | 0.01% | 567 |
|
|
2020
Q2 | $2.58M | Buy |
141,105
+9,752
| +7% | +$175K | 0.01% | 665 |
|
|
2020
Q1 | $2.05M | Buy |
131,353
+37,790
| +40% | +$804K | 0.01% | 598 |
|
|
2019
Q4 | $2M | Buy |
93,563
+61,156
| +189% | +$1.26M | 0.01% | 688 |
|
|
2019
Q3 | $606K | Buy |
32,407
+6,979
| +27% | +$144K | ﹤0.01% | 1030 |
|
|
2019
Q2 | $663K | Buy |
25,428
+21,506
| +548% | +$485K | ﹤0.01% | 924 |
|
|
2019
Q1 | $101K | Buy |
+3,922
| New | +$89.7K | ﹤0.01% | 1515 |
|
|
2016
Q4 | – | Sell |
-13,248
| Closed | -$486K | – | 1750 |
|
|
2016
Q3 | $486K | Buy |
+13,248
| New | +$380K | ﹤0.01% | 819 |
|
|
2016
Q2 | – | Sell |
-16,895
| Closed | -$351K | – | 1508 |
|
|
2016
Q1 | $351K | Buy |
16,895
+14,947
| +767% | +$369K | ﹤0.01% | 811 |
|
|
2015
Q4 | $59K | Buy |
1,948
+1,907
| +4,651% | +$57.8K | ﹤0.01% | 1114 |
|
|
2015
Q3 | $1K | Sell |
41
-465
| -92% | -$13.9K | ﹤0.01% | 1276 |
|
|
2015
Q2 | $16K | Buy |
506
+91
| +22% | +$3.48K | ﹤0.01% | 1105 |
|
|
2015
Q1 | $15K | Buy |
+415
| New | +$11.4K | ﹤0.01% | 1142 |
|
Other funds holding RIGL
SCM
VCM
CM
VPM
Acadian Asset Management's RIGL Position: Q2 2026 in Review
Acadian Asset Management reduced its Rigel Pharmaceuticals (RIGL) stake by 11% in Q2 2026, selling an estimated $2.31M and leaving 591,686 shares worth $23.1M. The position accounts for 0.03% of the portfolio, ranked #388.
Acadian Asset Management first reported a position in RIGL in Q1 2015 and has held it in 33 quarters since. 111 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.
- Acadian Asset Management held 591,686 shares of Rigel Pharmaceuticals worth $23.1M as of Q2 2026.
- Acadian Asset Management sold 74,740 Rigel Pharmaceuticals shares in Q2 2026, an estimated $2.31M.
- Rigel Pharmaceuticals made up 0.03% of Acadian Asset Management's portfolio in Q2 2026, its #388 holding.
- Acadian Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and has held it in 33 quarters since.
- 111 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.